Abstract:The DNA repair protein PARP-1 emerged as a valuable target in the treatment of tumor entities with deficiencies of BRCA1/2, such as breast cancer. More recently, the application of PARP inhibitors (PARPi) such as olaparib has been expanded to other cancer entities including colorectal cancer (CRC). We previously demonstrated that PARP-1 is overexpressed in human CRC and promotes CRC progression in a mouse model. However, acquired resistance to PARPi and cytotoxicity-mediated adverse effects limit their clinical applicability. Here, we detailed the role of PARP-1 as a therapeutic target in CRC and studied the efficacy of novel PARPi compounds in wildtype (WT) and DNA repair-deficient CRC cell lines together with the chemotherapeutics irinotecan (IT), 5-fluorouracil (5-FU), and oxaliplatin (OXA). Based on the ComPlat molecule archive, we identified novel PARPi candidates by molecular docking experiments in silico, which were then confirmed by in vitro PARP activity measurements. Two promising candidates (X17613 and X17618) also showed potent PARP-1 inhibition in a CRC cell-based assay. In contrast to olaparib, the PARPi candidates caused no PARP-1 trapping and, consistently, were not or only weakly cytotoxic in WT CRC cells and their BRCA2- or ATR-deficient counterparts. Importantly, both PARPi candidates did not affect the viability of nonmalignant human colonic epithelial cells. While both olaparib and veliparib increased the sensitivity of WT CRC cells towards IT, no synergism was observed for X17613 and X17618. Finally, we provided evidence that all PARPi (olaparib > veliparib > X17613 > X17618) synergize with chemotherapeutic drugs (IT > OXA) in a BRCA2-dependent manner in CRC cells, whereas ATR deficiency had only a minor impact. Collectively, our study identified novel lead structures with potent PARP-1 inhibitory activity in CRC cells but low cytotoxicity due to the lack of PARP-1 trapping, which synergized with IT in homologous recombination deficiency.

Generation and detection of two-photon coherent states in degenerate four-wave mixing.

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1

The complex universe of inactive PARP1

A two-step mechanism governing PARP1-DNA retention by PARP inhibitors

Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition

A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells

The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction

PARP1 Inhibitors: Antitumor Drug Design

CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors

PARP1: Structural insights and pharmacological targets for inhibition

Structural basis for allosteric PARP-1 retention on DNA breaks

Transcription–replication conflicts underlie sensitivity to PARP inhibitors

Molecular mechanism of PARP inhibitor resistance

Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response

Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials

Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation

Mechanism of Action of PARP Inhibitors

PARG inhibition induces nuclear aggregation of PARylated PARP1